AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30646948 — intervention group
Group type: COMPARATOR
Intervention: Control (routine follow-up)
Number of subjects: 771
Study 28246206 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/simtuzumab 700 mg
Number of subjects: 240
Study 28246206 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/simtuzumab 200 mg
Number of subjects: 240
Study 28246206 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/placebo
Number of subjects: 240
Study 26939315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Tianshu, Zusanli, Shangjuxu, Taichong, Sanyinjiao, Yintang, Baihui), once a day, 5 treatments a week for 4 weeks.
Number of subjects: 60
Study 26939315 — intervention group
Group type: COMPARATOR
Intervention: Lactulose oral solution, 15 mL three times a day for 4 weeks.
Number of subjects: 60
Study 26939315 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (same as above)
Number of subjects: 60
Study 26939315 — intervention group
Group type: COMPARATOR
Intervention: Lactulose oral solution (same as above)
Number of subjects: 60
Study 23936893 — intervention group
Group type: EXPERIMENTAL
Intervention: Research assistant‐directed distraction
Number of subjects: 99
Study 23936893 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐directed distraction
Number of subjects: 99
Study 23936893 — intervention group
Group type: COMPARATOR
Intervention: Typical care
Number of subjects: 99
Study 23936893 — intervention group
Group type: EXPERIMENTAL
Intervention: Distressed preneedle toddlers (regardless of treatment group)
Number of subjects: 99
Study 21592873 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge needle
Number of subjects: 50
Study 21592873 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 50
Study 21592873 — intervention group
Group type: COMPARATOR
Intervention: Both 22-gauge and 25-gauge needles
Number of subjects: 50
Study 18430242 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgrouping using a novel tool combined with targeted treatment delivered by trained physiotherapists
Number of subjects: 800
Study 18430242 — intervention group
Group type: COMPARATOR
Intervention: Best current care
Number of subjects: 800
Study 16942963 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 83
Study 16942963 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Exposure (SE)
Number of subjects: 83
Study 16942963 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 83
Study 16942963 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) and Standard Exposure (SE)
Number of subjects: 83
Study 12930428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intravesical sequential bacillus Calmette‐Guérin (BCG) and epirubicin
Number of subjects: 533
Study 12930428 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG alone
Number of subjects: 533
Study 12930428 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (50 or 80 mg)
Number of subjects: 533
Study 12930428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin 50 mg
Number of subjects: 533
Study 12930428 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 533
Study 12930428 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 533
Study 10837439 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 105
Study 10837439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 9377611 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 0
Study 9377611 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 0
Study 8170770 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 8170770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3816291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 0.125 mg
Number of subjects: 8
Study 3816291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 1.5 mg
Number of subjects: 8
Study 3816291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30593989 — intervention group
Group type: EXPERIMENTAL
Intervention: School success and peer support
Number of subjects: 768
Study 30593989 — intervention group
Group type: COMPARATOR
Intervention: Threat appraisals of interparental conflict
Number of subjects: 768
Study 29174623 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical and noninjection therapies
Number of subjects: 125
Study 26742872 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasable suture technique 1
Number of subjects: 90
Study 26742872 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasable suture technique 2
Number of subjects: 90
Study 26742872 — intervention group
Group type: EXPERIMENTAL
Intervention: Releasable suture technique 3
Number of subjects: 90
Study 25245413 — intervention group
Group type: COMPARATOR
Intervention: Normal-sized LA
Number of subjects: 5496
Study 25245413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilated LA
Number of subjects: 5496
Study 22001391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib (T) 600 mg twice a day × 14 days, Etoposide (E) 100 mg days 1‐3 and 8‐10
Number of subjects: 84
Study 22001391 — intervention group
Group type: COMPARATOR
Intervention: Tipifarnib (T) 400 mg twice a day × 14 days, Etoposide (E) 200 mg days 1‐3 and 8‐10
Number of subjects: 84
Study 22001391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipifarnib plus Etoposide in patients with a RASGRP1/APTX ratio of more than 5.2
Number of subjects: 84
Study 19848555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg) plus one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily
Number of subjects: 150
Study 19848555 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA (0.625 mg conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate) plus one Cal+D tablet daily
Number of subjects: 150
Study 19848555 — intervention group
Group type: COMPARATOR
Intervention: Control group (one Cal+D tablet only)
Number of subjects: 150
Study 16928395 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention program (seven sessions)
Number of subjects: 107
Study 16928395 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 15689198 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation followed by painful stimulation of the temple (ice applications)
Number of subjects: 27
Study 15689198 — intervention group
Group type: EXPERIMENTAL
Intervention: Optokinetic stimulation with painful stimulation of the temple (ice applications)
Number of subjects: 27
Study 15689198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand immersion in ice water during optokinetic stimulation
Number of subjects: 27
Study 11891813 — intervention group
Group type: EXPERIMENTAL
Intervention: WinRho-SD (25 or 50 microg/kg)
Number of subjects: 7
Study 9527081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent transdermal nitroglycerin patches (0.4, 0.8, or 1.6 mg/hour)
Number of subjects: 291
Study 9527081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 7608351 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled reduced smoking (progressive increase in the intercigarette interval)
Number of subjects: 128
Study 7608351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonscheduled reduced smoking (gradual reduction, no specific change in the intercigarette interval)
Number of subjects: 128
Study 7608351 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled nonreduced smoking (fixed intercigarette interval, no reductions in frequency)
Number of subjects: 128
Study 7608351 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonscheduled nonreduced smoking (no change in intercigarette interval or smoking frequency)
Number of subjects: 128
Study 2708843 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily dose of netilmicin
Number of subjects: 70
Study 2708843 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily doses of netilmicin
Number of subjects: 70
Study 29493280 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for primary caregivers
Number of subjects: 63
Study 29493280 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation alone
Number of subjects: 63
Study 27629750 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine treatment
Number of subjects: 80
Study 27629750 — intervention group
Group type: COMPARATOR
Intervention: Mere lifestyle intervention
Number of subjects: 80
Study 26374429 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-FU
Number of subjects: 1608
Study 26374429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 1608
Study 26374429 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Number of subjects: 1608
Study 26374429 — intervention group
Group type: COMPARATOR
Intervention: No oxaliplatin
Number of subjects: 1608
Study 24245707 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based exposure treatment
Number of subjects: 30
Study 24245707 — intervention group
Group type: COMPARATOR
Intervention: One-session exposure treatment (OST)
Number of subjects: 30
Study 21042231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 injections of TDV at months 0, 3.5, and 12 (TDV-TDV-TDV)
Number of subjects: 126
Study 21042231 — intervention group
Group type: COMPARATOR
Intervention: 1 injection of yellow fever vaccine (YF) at month 0, and 2 injections of TDV at months 3.5 and 12 (YF-TDV-TDV)
Number of subjects: 126
Study 21042231 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 injections of TDV
Number of subjects: 126
Study 19296144 — intervention group
Group type: EXPERIMENTAL
Intervention: Before-breakfast dosing of risedronate 5 mg daily
Number of subjects: 3112
Study 19296144 — intervention group
Group type: COMPARATOR
Intervention: Flexible dosing of risedronate 5 mg daily (2 h before and 2 h after any food and drink other than plain water)
Number of subjects: 3112
Study 17134335 — intervention group
Group type: EXPERIMENTAL
Intervention: Web administration of social desirability questionnaires
Number of subjects: 404
Study 17134335 — intervention group
Group type: COMPARATOR
Intervention: Laboratory administration of social desirability questionnaires
Number of subjects: 404
Study 17134335 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected online administration of social desirability questionnaires
Number of subjects: 404
Study 12956024 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-intervention programme of exercise and social support
Number of subjects: 20
Study 12956024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 10950818 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 11
Study 10950818 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 11
Study 9060551 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (2,250 mg) + Omeprazole for 14 days
Number of subjects: 20
Study 9060551 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Omeprazole for 14 days
Number of subjects: 20
Study 9060551 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR analysis
Number of subjects: 20
Study 9060551 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication
Number of subjects: 20
Study 9060551 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyclonal PCR in gastritis patients
Number of subjects: 20
Study 8154249 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carteolol 2%
Number of subjects: 9
Study 8154249 — intervention group
Group type: COMPARATOR
Intervention: Biological salt solution (control)
Number of subjects: 9
Study 3097668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-nasal buserelin
Number of subjects: 80
Study 3097668 — intervention group
Group type: COMPARATOR
Intervention: Oral danazol
Number of subjects: 80
Study 30116062 — intervention group
Group type: COMPARATOR
Intervention: Provincial hospitals
Number of subjects: 124
Study 27121850 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media exposure (Facebook and Twitter posts, boosted and retweeted); 74 manuscripts
Number of subjects: 152
Study 27121850 — intervention group
Group type: COMPARATOR
Intervention: Control (no social media exposure); 78 manuscripts
Number of subjects: 152
Study 24621228 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (responsive focal cortical stimulation)
Number of subjects: 191
Study 24621228 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 191
Study 22534594 — intervention group
Group type: EXPERIMENTAL
Intervention: RIME-structured scoring format
Number of subjects: 547
Study 20724336 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 20724336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18996864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS) containing glutamine, carbohydrates, and antioxidants
Number of subjects: 30
Study 18996864 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS)
Number of subjects: 30
Study 18996864 — intervention group
Group type: COMPARATOR
Intervention: Glutamine infusion alone
Number of subjects: 30
Study 18996864 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 16872926 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional prostheses (CP)
Number of subjects: 46
Study 16872926 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported prostheses (IP)
Number of subjects: 46
Study 16872926 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed
Number of subjects: 46
Study 14698357 — intervention group
Group type: EXPERIMENTAL
Intervention: Johrei
Number of subjects: 48
Study 14698357 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis
Number of subjects: 48
Study 14698357 — intervention group
Group type: COMPARATOR
Intervention: Mock neurofeedback relaxation control
Number of subjects: 48
Study 11078457 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Number of subjects: 31
Study 11078457 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 5 min)
Number of subjects: 31
Study 11078457 — intervention group
Group type: COMPARATOR
Intervention: Day 1 euglycemia (5.2 +/‐ 0.1 mmol/l)
Number of subjects: 31
Study 11078457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Number of subjects: 31
Study 10165528 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous (i.v.) antibacterial therapy
Number of subjects: 187
Study 10165528 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated regimen of intravenous antibacterials for 2 to 4 days followed by oral ciprofloxacin or oral enoxacin
Number of subjects: 187
Study 10165528 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch therapy
Number of subjects: 187
Study 7934684 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 150 micrograms/10 ml
Number of subjects: 40
Study 7934684 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study 3728446 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered mailed questionnaire
Number of subjects: 0
Study 3728446 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 0
Study 3728446 — intervention group
Group type: EXPERIMENTAL
Intervention: Home interview
Number of subjects: 0
Study 3728446 — intervention group
Group type: COMPARATOR
Intervention: Mail mode
Number of subjects: 0
Study 3728446 — intervention group
Group type: COMPARATOR
Intervention: Telephone and home interview modes
Number of subjects: 0
Study 31414370 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education given in Arabic
Number of subjects: 60
Study 31414370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education)
Number of subjects: 60
Study 30893230 — intervention group
Group type: EXPERIMENTAL
Intervention: No Sling
Number of subjects: 80
Study 30893230 — intervention group
Group type: COMPARATOR
Intervention: Sling
Number of subjects: 80
Study 27938990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) once a week for 5 weeks
Number of subjects: 126
Study 27938990 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment once a week for 5 weeks
Number of subjects: 126
Study 27938990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) after a 4-week break, once a week for 5 weeks
Number of subjects: 126
Study 27938990 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment after a 4-week break, once a week for 5 weeks
Number of subjects: 126
Study 27938990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Energy Linear Shockwave Therapy (LLi‐ESWT)
Number of subjects: 126
Study 27938990 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 126
Study 25261241 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens
Number of subjects: 114
Study 25261241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL)
Number of subjects: 114
Study 25261241 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 23862237 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Xuanju Capsule + Tamsulosin Hydrochloride
Number of subjects: 242
Study 23862237 — intervention group
Group type: COMPARATOR
Intervention: Quinolinone antibiotics + Tamsulosin Hydrochloride
Number of subjects: 242
Study 21493665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight closed loop delivery of insulin after a medium sized evening meal (60 g of carbohydrates) at 1900.
Number of subjects: 24
Study 21493665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight closed loop delivery of insulin after a larger evening meal (100 g of carbohydrates) at 2030, accompanied by white wine (0.75 g/kg ethanol).
Number of subjects: 24
Study 21493665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled data analysis of overnight closed loop delivery of insulin.
Number of subjects: 24
Study 21493665 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight closed loop delivery of insulin.
Number of subjects: 24
Study 19558835 — intervention group
Group type: EXPERIMENTAL
Intervention: Local and general dexamethasone administration
Number of subjects: 78
Study 19558835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone injection
Number of subjects: 78
Study 19558835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection
Number of subjects: 78
Study 19558835 — intervention group
Group type: COMPARATOR
Intervention: Comparison among all groups
Number of subjects: 78
Study 16925616 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial Trial Intervention (STI)
Number of subjects: 57
Study 16925616 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatments
Number of subjects: 57
Study 16925616 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 57
Study 16925616 — intervention group
Group type: COMPARATOR
Intervention: Not-for-profit facilities
Number of subjects: 57
Study 15191380 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 10 mg/kg for 5 days
Number of subjects: 107
Study 15191380 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 20 mg/kg daily in three doses for 7 days
Number of subjects: 107
Study 11465638 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg moclobemide during the first week, and 600 mg afterwards
Number of subjects: 12
Study 11465638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9157942 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d of eicosapentaenoic and docosahexaenoic acids (fish oil)
Number of subjects: 78
Study 9157942 — intervention group
Group type: COMPARATOR
Intervention: Corn oil placebo
Number of subjects: 78
Study 8354983 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment with beta blockers and diuretics for a mean follow-up of 25 months
Number of subjects: 1627
Study 8354983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study 3440385 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of oxygen administration
Number of subjects: 0
Study 3440385 — intervention group
Group type: COMPARATOR
Intervention: 12 hours of oxygen administration
Number of subjects: 0
Study 31578132 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 15
Study 31578132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30632775 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthMpowerment (HMP) online intervention
Number of subjects: 48
Study 27532605 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg∙kg‐1)
Number of subjects: 16
Study 23865977 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 30
Study 23865977 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30
Study 22383591 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based care
Number of subjects: 523
Study 22383591 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 523
Study 20441132 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-digit synesthesia (SE)
Number of subjects: 1
Study 20441132 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1
Study 18395728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 72
Study 18395728 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 72
Study 15825785 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen/ibuprofen
Number of subjects: 150
Study 15825785 — intervention group
Group type: EXPERIMENTAL
Intervention: flurbiprofen/flurbiprofen
Number of subjects: 150